Arbutus Biopharma (ABUS) – Hot Downgrades
-
Baird Downgrades Arbutus Biopharma (ABUS) to Neutral; Upside from Moderna IPR Win Priced In
-
Chardan Capital Markets Downgrades Arbutus Biopharma (ABUS) to Neutral; Safety Risk Overwhelms Promising Efficacy
-
Back to ABUS Stock Lookup